- £1.55bn
- £1.61bn
- £658.10m
Europe Research Roundup: Azelis, Barratt Redrow, ArcelorMittal
Brief: Genus Expects FY25 Adj. PBT At Least £68 Mln Excluding PRP Milestone Receipt
Genus - FY25 Trading Update
UK's Genus secures FDA approval for PRP gene edit; shares soar (updated)
UK's Genus secures FDA approval for PRP gene edit; shares soar
UK's Genus soars on US FDA nod for gene-edited pigs
Genus - Notification of Major Holdings
Notification of Major Holdings
Genus - Director/PDMR Shareholding
Genus - Notification of Major Holdings
Brief: Genus Appoints Andy Russell As CFO
Genus - Appointment of Chief Financial Officer Designate
Genus - Director/PDMR Shareholding
Brief: Genus Says HY Adjusted PBT Increased 21%
Genus - Interim Results
Genus - Non-Executive Director Retirement
UK's Genus soars on top-end annual profit forecast
Brief: Genus Expects H1 FY25 Adj PBT Of At Least 35 Mln Stg In Actual Currency
Genus - Half Year Trading Update – Ahead of expectations